Bausch + Lomb

Bausch + Lomb

NJ - Bridgewater
Biotechnology1 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Ophthalmology

Bausch + Lomb is a life sciences company focused on Ophthalmology.

Ophthalmology
Funding Stage
PUBLIC
Open Jobs
0

Products & Portfolio (23)

27 discontinued products not shown

ACANYA
clindamycin phosphate and benzoyl peroxide
Peak
TOPICAL · GEL
12.1 Mechanisms of Action Clindamycin: Clindamycin is a lincosamide antibacterial [see ] . Benzoyl Peroxide: Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic effects but the precise mechanism of action is unknown. 12.3 Pharmacokinetics The systemic absorption of clindamycin was investigated in an open-label, multiple-dose trial in 16 adult subjects with moderate to severe acne vulgaris treated with 1 gram of ACANYA Gel applied to the face once daily for 30 days. Twelve subjects (75%) had at least one quantifiable clindamycin plasma concentration above the lower limit of quantification (LOQ = 0.5 ng/mL) on Day 1 or Day 30. On Day 1, the mean (± standard deviation) peak plasma concentration (C max ) was 0.78 ± 0.22 ng/mL (n=9 with measurable concentrations), and the mean AUC 0-t was 5.29 ± 0.81 h.ng/mL (n=4). On Day 30, the mean C max was 1.22 ± 0.88 ng/mL (n=10), and the mean AUC 0-t was 8.42 ± 6.01 h.ng/mL (n=6). Clindamycin plasma concentrations were below LOQ in all subjects at 24 hours post-dose on the three tested days (Day 1, 15, and 30). Benzoyl peroxide has been shown to be absorbed by the skin where it is converted to benzoic acid. 12.4 Microbiology Clindamycin binds to the 50S ribosomal subunits of susceptible bacteria and prevents elongation of peptide chains by interfering with peptidyl transfer, thereby suppressing bacterial protein synthesis. Clindamycin and benzoyl peroxide individually have been shown to havein vitro activity against Propionibacterium acnes , an organism which has been associated with acne vulgaris; however, the clinical significance of this activity against P. acnes is not known. P. acnes resistance to clindamycin has been documented. Resistance to clindamycin is often associated with resistance to erythromycin.
2008
8
ALAWAY
ketotifen fumarate
LOE Approaching
OPHTHALMIC · SOLUTION/DROPS
2006
30
ALREX
loteprednol etabonate
LOE Approaching
OPHTHALMIC · SUSPENSION/DROPS
CLINICAL PHARMACOLOGY Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A 2 . Corticosteroids are capable of producing a rise in intraocular pressure. Loteprednol etabonate is structurally similar to other corticosteroids. However, the number 20 position ketone group is absent. It is highly lipid soluble which enhances its penetration into cells. Loteprednol etabonate is synthesized through structural modifications of prednisolone-related compounds so that it will undergo a predictable transformation to an inactive metabolite. Based upon in vivo and in vitro preclinical metabolism studies, loteprednol etabonate undergoes extensive metabolism to inactive carboxylic acid metabolites. Results from a bioavailability study in normal volunteers established that plasma levels of loteprednol etabonate and Δ cortienic acid etabonate (PJ 91), its primary, inactive metabolite, were below the limit of quantitation (1 ng/mL) at all sampling times. The results were obtained following the ocular administration of one drop in each eye of 0.5% loteprednol etabonate 8 times daily for 2 days or 4 times daily for 42 days. This study suggests that limited (<1 ng/mL) systemic absorption occurs with Loteprednol Etabonate Ophthalmic Suspension, 0.2%. Clinical Studies: In two double-masked, placebo-controlled six-week environmental studies of 268 patients with seasonal allergic conjunctivitis, Loteprednol Etabonate Ophthalmic Suspension, 0.2%, when dosed four times per day was superior to placebo in the treatment of the signs and symptoms of seasonal allergic conjunctivitis. Loteprednol Etabonate Ophthalmic Suspension, 0.2% provided reduction in bulbar conjunctival injection and itching, beginning approximately 2 hours after instillation of the first dose and throughout the first 14 days of treatment.
1998
30
ANCOBON
flucytosine
LOE Approaching
ORAL · CAPSULE
CLINICAL PHARMACOLOGY Flucytosine is rapidly and virtually completely absorbed following oral administration. ANCOBON is not metabolized significantly when given orally to man. Bioavailability estimated by comparing the area under the curve of serum concentrations after oral and intravenous administration showed 78% to 89% absorption of the oral dose. Peak serum concentrations of 30 to 40 mcg/mL were reached within 2 hours of administration of a 2 g oral dose to normal subjects. Other studies revealed mean serum concentrations of approximately 70 to 80 mcg/mL 1 to 2 hours after a dose in patients with normal renal function receiving a 6-week regimen of flucytosine (150 mg/kg/day given in divided doses every 6 hours) in combination with amphotericin B. The half-life in the majority of healthy subjects ranged between 2.4 and 4.8 hours. Flucytosine is excreted via the kidneys by means of glomerular filtration without significant tubular reabsorption. More than 90% of the total radioactivity after oral administration was recovered in the urine as intact drug. Flucytosine is deaminated (probably by gut bacteria) to 5-fluorouracil. The area under the curve (AUC) ratio of 5-fluorouracil to flucytosine is 4%. Approximately 1% of the dose is present in the urine as the α-fluoro-β-ureido-propionic acid metabolite. A small portion of the dose is excreted in the feces. The half-life of flucytosine is prolonged in patients with renal insufficiency; the average half-life in nephrectomized or anuric patients was 85 hours (range: 29.9 to 250 hours). A linear correlation was found between the elimination rate constant of flucytosine and creatinine clearance. In vitro studies have shown that 2.9% to 4% of flucytosine is protein-bound over the range of therapeutic concentrations found in the blood. Flucytosine readily penetrates the blood-brain barrier, achieving clinically significant concentrations in cerebrospinal fluid. Pharmacokinetics in Pediatric Patients Limited data are available regarding the pharmacokinetics of ANCOBON administered to neonatal patients being treated for systemic candidiasis. After five days of continuous therapy, median peak levels in infants were 19.6 mcg/mL, 27.7 mcg/mL, and 83.9 mcg/mL at doses of 25 mg/kg (N=3), 50 mg/kg (N=4), and 100 mg/kg (N=3), respectively. Mean time to peak serum levels was of 2.5 ± 1.3 hours, similar to that observed in adult patients. A good deal of interindividual variability was noted, which did not correlate with gestational age. Some patients had serum levels > 100 mcg/mL, suggesting a need for drug level monitoring during therapy. In another study, serum concentrations were determined during flucytosine therapy in two patients (total assays performed =10). Median serum flucytosine concentrations at steady state were calculated to be 57 ± 10 mcg/mL (doses of 50 to 125 mg/kg/day, normalized to 25 mg/kg per dose for comparison). In three infants receiving flucytosine 25 mg/kg/day (four divided doses), a med
1971
30
APLENZIN
bupropion hydrobromide
LOE Approaching
ORAL · TABLET, EXTENDED RELEASE
unknown, as is the case with other antidepressants. However, it is presumed that this action is mediated by noradrenergic and/or dopaminergic mechanisms. Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine and does not inhibit monoamine oxidase or the reuptake of serotonin.
major depressive disorder (MDD)seasonal affective disorder (SAD)defined by the Diagnostic+2 more
2008
25
ARAZLO
tazarotene
Peak
TOPICAL · LOTION
form, tazarotenic acid, the carboxylic acid of tazarotene, by deesterification. Tazarotenic acid binds to all three members of the retinoic acid receptor (RAR) family: RARα, RARβ and RARγ, but shows relative selectivity for RARβ, and RARγ and may modify gene expression. The clinical significance of these findings for the treatment of acne vulgaris is unknown.
2019
0
ATIVAN
lorazepam
LOE Approaching
ORAL · TABLET
CLINICAL PHARMACOLOGY Studies in healthy volunteers show that in single high doses Ativan (lorazepam) has a tranquilizing action on the central nervous system with no appreciable effect on the respiratory or cardiovascular systems. Ativan (lorazepam) is readily absorbed with an absolute bioavailability of 90%. Peak concentrations in plasma occur approximately 2 hours following administration. The peak plasma level of lorazepam from a 2 mg dose is approximately 20 ng/mL. The mean half-life of unconjugated lorazepam in human plasma is about 12 hours and for its major metabolite, lorazepam glucuronide, about 18 hours. At clinically relevant concentrations, lorazepam is approximately 85% bound to plasma proteins. Ativan (lorazepam) is rapidly conjugated at its 3-hydroxy group into lorazepam glucuronide which is then excreted in the urine. Lorazepam glucuronide has no demonstrable central nervous system (CNS) activity in animals. The plasma levels of lorazepam are proportional to the dose given. There is no evidence of accumulation of lorazepam on administration up to 6 months. Studies comparing young and elderly subjects have shown that advancing age does not have a significant effect on the pharmacokinetics of lorazepam. However, in one study involving single intravenous doses of 1.5 to 3 mg of Ativan Injection, mean total body clearance of lorazepam decreased by 20% in 15 elderly subjects of 60 to 84 years of age compared to that in 15 younger subjects of 19 to 38 years of age.
anxiety disordersfor the short-term relief of the symptoms of anxietyanxiety associated with depressive symptoms+1 more
1977
30
ATROPINE SULFATE
atropine sulfate
Peak
OPHTHALMIC · SOLUTION/DROPS
muscarine-like actions of acetylcholine and is therefore classified as an anti-muscarinic agent. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does not distinguish among the M1, M2, and M3 subgroups of muscarinic receptors. The pupillary constrictor muscle depends on muscarinic cholinoceptor activation. This activation is blocked by topical atropine resulting in unopposed sympathetic dilator activity and mydriasis. Atropine also weakens the contraction of the ciliary muscle, or cycloplegia. Cycloplegia results in loss of the ability to accommodate such that the eye cannot focus for near vision.
2022
30
BACITRACIN ZINC AND POLYMYXIN B SULFATE
bacitracin zinc and polymyxin b sulfate
Post-LOE
OPHTHALMIC · OINTMENT
CLINICAL PHARMACOLOGY Polymyxin B sulfate attacks gram-negative bacilli, including virtually all strains of Pseudomonas aeruginosa and Haemophilus influenzae species. Bacitracin is active against most gram-positive bacilli and cocci including hemolytic streptococci.
1995
30
BENZAMYCIN
erythromycin and benzoyl peroxide
LOE Approaching
TOPICAL · GEL
CLINICAL PHARMACOLOGY The exact mechanism by which erythromycin reduces lesions of acne vulgaris is not fully known; however, the effect appears to be due in part to the antibacterial activity of the drug. Benzoyl peroxide has a keratolytic and desquamative effect which may also contribute to its efficacy. Benzoyl peroxide has been shown to be absorbed by the skin where it is converted to benzoic acid.
1984
30
BEPREVE
bepotastine besilate
LOE Approaching
OPHTHALMIC · SOLUTION/DROPS
active, direct H1-receptor antagonist and an inhibitor of the release of histamine from mast cells.
itching associated with signssymptoms of allergic conjunctivitisitching associated with allergic conjunctivitis
2009
30
BESIVANCE
besifloxacin
Peak
SMOPHTHALMIC · SUSPENSION/DROPS
[see Microbiology ( )] .
bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans*CDC coryneform group GCorynebacterium pseudodiphtheriticum*+14 more
2009
8
View all 23 products

Pipeline & Clinical Trials

samfilcon A Lenses with EPG01 Packaging Solution
Contact Lens Wearer
N/A
Clinical Trials (1)
NCT051269532-Hour Dispensing Evaluation of Samfilcon A Lenses With EPG01 Packaging Solution Compared to Commercially Available B+L Ultra Lenses
N/A
B&L Investigational Contact Lens
Myopia
N/A
Clinical Trials (1)
NCT01449526A Study to Evaluate the Safety and Efficacy of a New Silicone Hydrogel Contact Lens Design
N/A
Bausch & Lomb Multi-Purpose Solution
Contact Lens Solutions
N/A
Clinical Trials (1)
NCT00710879Evaluation of a Multi-Purpose Solution
N/A
CBL-102 eye drops
Dry Eye
N/A
Clinical Trials (1)
NCT03368404A Study to Evaluate the Performance and Safety of CBL-102 Versus Vismed® Multi Eye Drops in the Management of Dry Eye
N/A
Test lens
Myopia
N/A
Clinical Trials (1)
NCT01309880Evaluation of a New Silicone Hydrogel Contact Lens
N/A
Experimental- Soflens
Myopia
N/A
Clinical Trials (1)
NCT01300065Evaluation of Two Daily Disposable Contact Lenses.
N/A
REVIVE samfilcon B custom toric contact lenses
Astigmatism
N/A
Clinical Trials (1)
NCT06785194Revive Toric RWE Study
N/A
Investigational Toric Lens
Myopia
N/A
Clinical Trials (1)
NCT01309867A Study to Evaluate the Performance of Two Designs of Soft Toric Lenses
N/A
Eyefill® S.C.
Cataract
N/A
Clinical Trials (1)
NCT06767917A Post-Market Clinical Follow-Up on Safety and Performance of the Ophthalmic Viscoelastic Devices Eyefill SC and Eyefill MB
N/A
kalifilcon A Daily Disposable Toric
Myopia
N/A
Clinical Trials (1)
NCT053200421-Week Dispensing Evaluation of Kalifilcon A Toric Contact Lenses Compared to Ultra for Astigmatism
N/A
enVista MX60EFH trifocal intraocular lenses
Cataract
N/A
Clinical Trials (1)
NCT04224155Clinical Study to Evaluate the Safety and Performance of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens in Subjects Undergoing Cataract Extraction
N/A
Safety of Overnight Corneal Reshaping Lenses
Keratitis
N/A
Clinical Trials (1)
NCT01272271Safety of Overnight Corneal Reshaping Lenses
N/A
ISTA Tears
Dry Eye Disease
N/A
Clinical Trials (1)
NCT01650584Evaluation of Ocular Comfort With ISTA Tears vs Systane
N/A
Lubricating and Rewetting Drops
Dry Eye
N/A
Clinical Trials (1)
NCT01267656Study to Evaluate a Contact Lens Lubricating and Rewetting Drop
N/A
kalifilcon A Daily Disposable Toric
Astigmatism
N/A
Clinical Trials (1)
NCT06069609Orientation Characteristics of Daily Disposable Toric Contact Lenses
N/A
N/A
Clinical Trials (1)
NCT03681808Evaluate the Safety and Effectiveness of the Biotrue ONEday for Astigmatism
N/A
Technolas 217z Zyoptix Laser
Hyperopia
N/A
Clinical Trials (1)
NCT00348205A Study to Evaluate the Safety and Effectiveness of the Technols 217z Zyoptix System for Hyperopia
N/A
Next Generation Diagnostic Instrument
Healthy
N/A
Clinical Trials (1)
NCT00347594A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI)
N/A
enVista MX60E
Cataract
N/A
Clinical Trials (1)
NCT03603600Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens
N/A
Senofilcon C
Myopia
N/A
Clinical Trials (1)
NCT03351101Clinical Study of Approved Contact Lenses
N/A
B&L Investigational Contact Lens
Corneal Deformity
N/A
Clinical Trials (1)
NCT02258139Study to Evaluate the Product Performance of a New Silicone Hydrogel Contact Lens
N/A
N/A
Clinical Trials (1)
NCT02452840Photodynamic Therapy for PDA in NV AMD
N/A
Evaluation of the Bausch & Lomb PureVision Under Nighttime Driving Conditions
Astigmatism
N/A
Clinical Trials (1)
NCT00581659Evaluation of the Bausch & Lomb PureVision Under Nighttime Driving Conditions
N/A
Custom Samfilcon B Contact Lenses
Contact Lens Wear
N/A
Clinical Trials (1)
NCT03897712A Study to Evaluate the Safety and Effectiveness of a Silicone Hydrogel Custom Contact Lens When Compared to Alden Optical HP Sphere Lens
N/A
Bausch + Lomb
Myopia
N/A
Clinical Trials (1)
NCT06305663A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children
N/A
orthokeratology lens
Myopia
N/A
Clinical Trials (1)
NCT05984290Study of Safety and Effectiveness of the Boston Orthokeratology Shaping Lens in the Arise Orthokeratology Lens
N/A
SofLens Daily Disposable
Myopia
N/A
Clinical Trials (1)
NCT00902850One-Day Dispensing Clinical Evaluation of SofLens Daily Disposable Lenses Compared to a Marketed 1 Day Contact Lens
N/A
kalifilcon A
Myopia
N/A
Clinical Trials (1)
NCT04901897Product Performance of a New Silicone Hydrogel Contact Lens
N/A
Trulign™ Toric IOL
Cataract
N/A
Clinical Trials (1)
NCT02394379Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber IOL
N/A
kalifilcon A Daily Disposable Multifocal
Presbyopia
N/A
Clinical Trials (1)
NCT053259311-Week Dispensing Evaluation of Kalifilcon A Daily Disposable Multifocal Compared to Ultra for Presbyopia
N/A
Bausch & Lomb Multipurpose Solution - Rub Care
Contact Lens Solutions
N/A
Clinical Trials (1)
NCT00636363Safety and Efficacy of a Bausch & Lomb Multipurpose Solution When Compared to Ciba Vision Aquify Multipurpose Solution
N/A
Prolensa
Cataract
N/A
Clinical Trials (1)
NCT01847638Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
N/A
Complete MPS
Contact Lens Wear
N/A
Clinical Trials (1)
NCT02701556A Safety and Effectiveness Study of a New Contact Lens Cleaning and Disinfecting Solution
N/A
N/A
Clinical Trials (1)
NCT01749241Efficacy of Loteprednol Ointment Following Eyelid Surgery
N/A
Contact Lens Wear
Dry Eye
N/A
Clinical Trials (1)
NCT01317030Tear Evaluation Between Habitual Contact Lens Wearers and Non Contact Lens Wearers
N/A
IC-8 Apthera IOL New Enrollment Post Approval Study
Cataract
N/A
Clinical Trials (1)
NCT06060041IC-8 Apthera IOL New Enrollment Post Approval Study
N/A
BL-3100-NBR03 multi-purpose solution
Refractive Ametropia
N/A
Clinical Trials (1)
NCT05565937A Study to Evaluate the Safety and Effectiveness of a Contact Lens Cleaning and Disinfecting Solution
N/A
Investigational lens
Myopia
N/A
Clinical Trials (1)
NCT01309906Evaluation of the Feasibility a New Silicone Hydrogel Contact Lens
N/A
Toric intraocular MX60T lens
Corneal Astigmatism
N/A
Clinical Trials (1)
NCT03633851Toric IOL vs Non-toric IOL With LRI for Corneal Astigmatism
N/A
N/A
Clinical Trials (1)
NCT02457026Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD
N/A
Daily disposable cosmetic tint lens
Myopia
N/A
Clinical Trials (1)
NCT01230554Product Performance of a Daily Disposable Contact Lens
N/A
enVista Aspire EA IOLs
Cataract
N/A
Clinical Trials (1)
NCT06333028A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction
N/A
LD127025 MF
Presbyopia
N/A
Clinical Trials (1)
NCT01959178A Study to Evaluate a Mid Add Multi-Focal Soft Contact Lens
N/A
ABT12 Multi-Purpose Solution
Contact Lens Wear
N/A
Clinical Trials (1)
NCT03897751A Safety and Effectiveness Study of BL-ABT12 Multi-Purpose Solution for Use by Participants With Soft Contact Lenses
N/A
Kalifilcon Toric Lens
Astigmatism
N/A
Clinical Trials (1)
NCT06098937Kalifilcon A Toric Compared to Commercially Available Lenses
N/A
IOL implantation
Cataract
N/A
Clinical Trials (1)
NCT01615861Evaluation of Clinical Outcomes Following Implantation of a Sub-2mm Hydrophilic MICS Intraocular Lens
N/A
PureVision2 HD contact lenses
Myopia
N/A
Clinical Trials (1)
NCT01416142A Study to Evaluate the Product Performance of the PureVision®2 High Definition (HD) Contact Lens
N/A
Contact lens correction of aphakia
Congenital Cataract
N/A
Clinical Trials (1)
NCT00212134Infant Aphakia Treatment Study (IATS)
N/A
TENEO 317 Model 2 excimer laser
Myopia
N/A
Clinical Trials (1)
NCT06618547Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia With or Without Astigmatism by Transepithelial Photorefractive Keratectomy
N/A
enVista Toric
Corneal Astigmatism
N/A
Clinical Trials (1)
NCT05075746Retrospective Chart Review of enVista Toric 0.9D Intraocular Lenses
N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 266 approved products, 150 clinical trials
Top TAs: Ophthalmology, Cardiovascular, Immunology
H-1B (2023): 1 approval
Portfolio Health
Pre-Launch17 (6%)
Growth3 (1%)
Peak21 (8%)
LOE Approaching118 (44%)
Post-LOE107 (40%)
266 total products
Therapeutic Area Focus
Ophthalmology
10 marketed149 pipeline
Cardiovascular
17 marketed11 pipeline
Immunology
20 marketed
Dermatology
16 marketed
Neurology
14 marketed1 pipeline
Respiratory
4 marketed
Metabolic Diseases
3 marketed1 pipeline
Marketed
Pipeline

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 3 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub